ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD.

Anhui Anke Biotechnology (Group) Co., Ltd.

300009

CNE100000GY2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-14 EDT			5-day change	1st Jan Change
10.24 ^CNY	-0.87%		-4.30%	+0.20%

04-25	Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-27	Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Anhui Anke Biotechnology Co., Ltd. Approves Cash Dividend for 2022

April 21, 2023 at 03:38 pm

Anhui Anke Biotechnology (Group) Co., Ltd. announced that at the AGM held on 20 April 2023 approved Cash dividend/10 shares (tax included): CNY 2.50000000 for 2022.

Latest news about Anhui Anke Biotechnology (Group) Co., Ltd.

Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Anke Biotechnology's Unit Passes US FDA Workplace Inspection	02-18	MT
Anhui Anke Biotechnology Co., Ltd. agreed to acquire 11.31% stake in Anhui Xinhuakun Biological Engineering Co., Ltd. from a group of shareholders for CNY 10.3 million.	12-12	CI
Anhui Anke Biotechnology Gets Nod to Market Breast Cancer Drug	11-01	MT
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Anhui Anke Biotechnology Co., Ltd. Announces Board Elections	22-12-26	CI
Anhui Anke Biotechnology Unit Gets Regulatory Nod For Anti-Postpartum Hemorrhage Drug	22-12-23	MT
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-24	CI
Tranche Update on Anhui Anke Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 8, 2022.	22-08-08	CI
Anhui Anke Biotechnology Co., Ltd.'s Equity Buyback announced on February 8, 2022, has expired with 4,187,406 shares, representing 0.26% for CNY 40.05 million.	22-08-06	CI
Tranche Update on Anhui Anke Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 8, 2022.	22-07-04	CI
Anhui Anke Biotech to Form mRNA Vaccine JV With Startup	22-05-17	MT
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Tranche Update on Anhui Anke Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 8, 2022.	22-04-06	CI
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Anhui Anke Biotechnology Co., Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.	22-02-07	CI
Anhui Anke Biotechnology Co., Ltd. authorizes a Buyback Plan.	22-02-06	CI
Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI
Anhui Anke Biotechnology Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-19	CI
China stocks fall as Beijing's crackdown fears hit sentiment	21-08-05	RE

Chart Anhui Anke Biotechnology (Group) Co., Ltd.

Duration

Period

Chart Anhui Anke Biotechnology (Group) Co., Ltd.

More charts

Anhui Anke Biotechnology (Group) Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of biological products, Chinese patent drugs, chemical synthetic drugs, peptide drugs and nucleic acid detection products. The Companyâs main products include recombinant human interferon alfa-2b series, recombinant human growth hormone, peptides Active Pharmaceutical Ingredients (APIs), customized peptides, deoxyribonucleic acid (DNA) fluorescence detection kit, silica beads extraction kit, anti-sperm antibody test kit, pain relieving ointment, amoxicillin granules and capsules, cefaclor dispersible tablets and adefovir dipivoxil tablets, among others. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Anhui Anke Biotechnology (Group) Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.24 CNY

Average target price

19.54 CNY

Spread / Average Target

+90.82%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD.	+0.20%	2.37B
CSL LIMITED	+0.10%	91.42B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	41.08B
BIOGEN INC.	-9.06%	34.26B
UCB	+54.56%	25.27B
INCYTE CORPORATION	-9.14%	12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.11%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.61%	11.42B
SWEDISH ORPHAN BIOVITRUM AB	+5.99%	9.16B
INNOVENT BIOLOGICS, INC.	-6.90%	8.22B

Biopharmaceuticals

Anhui Anke Biotechnology (Group) Co., Ltd.

Equities

300009

CNE100000GY2

Pharmaceuticals

Anhui Anke Biotechnology Co., Ltd. Approves Cash Dividend for 2022

Latest news about Anhui Anke Biotechnology (Group) Co., Ltd.

Chart Anhui Anke Biotechnology (Group) Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Anhui Anke Biotechnology (Group) Co., Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals